PDCD1 and neoplasm: When combined with immune checkpoint inhibitors, ATRA has been shown in preclinical models of mesothelioma, fibrosarcoma, and NSCLC to reduce MDSC accumulation and promote an interferon-driven, CD8+ T cell-enriched tumor milieu, ultimately enhancing the response to anti-PD-1 therapy [116].